NASDAQ:MIRM Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis $100.64 +1.87 (+1.89%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$100.70 +0.06 (+0.06%) As of 08/14/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mirum Pharmaceuticals Stock (NASDAQ:MIRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mirum Pharmaceuticals alerts:Sign Up Key Stats Today's Range$96.73▼$101.3150-Day Range$93.58▼$128.5752-Week Range$63.23▼$130.00Volume503,783 shsAverage Volume755,791 shsMarket Capitalization$6.53 billionP/E RatioN/ADividend YieldN/APrice Target$137.33Consensus RatingModerate Buy Company Overview Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist. Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage. Maralixibat has achieved regulatory approval in the United States for the treatment of cholestatic pruritus in patients with Alagille syndrome and is under review or in clinical development for other rare cholestatic conditions, including progressive familial intrahepatic cholestasis (PFIC). In addition to its lead compound, Mirum maintains a pipeline of product candidates aimed at expanding the therapeutic options available to patients with orphan liver diseases. Founded in 2016 and headquartered in Brisbane, California, Mirum Pharmaceuticals operates with a patient-centric approach that emphasizes collaboration with advocacy groups and key opinion leaders in hepatology. Under the leadership of President and Chief Executive Officer Derek Chalmers, the company is actively pursuing regulatory approvals and commercial partnerships to bring its therapies to patients in the United States and international markets.AI Generated. May Contain Errors. Read More Mirum Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreMIRM MarketRank™: Mirum Pharmaceuticals scored higher than 70% of companies evaluated by MarketBeat, and ranked 224th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingMirum Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMirum Pharmaceuticals has a consensus price target of $137.33, representing about 36.5% upside from its current price of $100.64.Amount of Analyst CoverageMirum Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Mirum Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.31) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -6.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -6.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Mirum Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.46% of the float of Mirum Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 12.05, which indicates bearish sentiment.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently decreased by 6.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.57 News SentimentMirum Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Mirum Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest5 people have searched for MIRM on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows6 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,763,562.00 in company stock.Percentage Held by Insiders8.32% of the stock of Mirum Pharmaceuticals is held by insiders.Percentage Held by InstitutionsMirum Pharmaceuticals has minimal institutional ownership at this time.Read more about Mirum Pharmaceuticals' insider trading history. Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MIRM Stock News HeadlinesMirum Pharmaceuticals (NASDAQ:MIRM) Rating Lowered to "Sell" at Wall Street Zen2 hours ago | americanbankingnews.comWhy Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's NextAugust 13 at 2:59 PM | finance.yahoo.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $599,499.90 in StockAugust 13 at 6:52 AM | insidertrades.comJ.P. Morgan Keeps Their Buy Rating on Mirum Pharmaceuticals (MIRM)August 13 at 4:07 AM | theglobeandmail.comMirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call TranscriptAugust 13 at 4:07 AM | finance.yahoo.comChristopher Peetz Sells 20,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) StockAugust 12, 2026 | insidertrades.comInsider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $193,733.60 in StockAugust 6, 2026 | insidertrades.comSee More Headlines MIRM Stock Analysis - Frequently Asked Questions How have MIRM shares performed this year? Mirum Pharmaceuticals' stock was trading at $78.99 on January 1st, 2026. Since then, MIRM shares have increased by 27.4% and is now trading at $100.64. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) posted its earnings results on Wednesday, August, 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.32. The business's quarterly revenue was up 37.9% on a year-over-year basis. Read the conference call transcript. When did Mirum Pharmaceuticals IPO? Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. Who are Mirum Pharmaceuticals' major shareholders? Mirum Pharmaceuticals' top institutional shareholders include Jupiter Topco LLC (9.10%), BlackRock Inc. (7.20%), William Blair Investment Management LLC (2.16%) and Bank of New York Mellon Corp (1.10%). Insiders that own company stock include Patrick J Heron, Christopher Peetz, Lara Longpre, Peter Radovich, Eric Bjerkholt, Pamela Vig, Joanne Quan, Laura Brege, Jolanda Howe, Saira Ramasastry and Michael G Grey. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings8/05/2026Today8/15/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 10 days, MIRM's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MIRM CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees140Year Founded2018Price Target and Rating Average Price Target for Mirum Pharmaceuticals$137.33 High Price Target$165.00 Low Price Target$118.00 Potential Upside/Downside+36.5%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($14.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.36 million Net Margins-139.18% Pretax Margin-138.74% Return on Equity-36.28% Return on Assets-8.54% Debt Debt-to-Equity Ratio1.28 Current Ratio2.86 Quick Ratio2.74 Sales & Book Value Annual Sales$521.31 million Price / Sales12.53 Cash Flow$0.05 per share Price / Cash Flow1,974.15 Book Value($0.16) per share Price / Book-629.00Miscellaneous Outstanding Shares64,930,000Free Float59,530,000Market Cap$6.53 billion OptionableOptionable Beta0.52 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:MIRM) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThe Greatest Wealth Transfer Since the Internet Boom Just StartedWall Street forensic accountant Joel Litman - who flagged the 2008 crash months early and called the 2020 COVI...Altimetry | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIRM Stock Alerts